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Abstract 
At the heart of cancer as a pathological process lies uncontrolled cellular proliferation, 
mediated by dysregulation of the cell cycle machinery and activation of cyclin dependent 
kinase (CDKs) to promote of cell cycle progression. First generation non-selective CDK 
inhibitors were hampered by toxicity and lack of efficacy. A new generation of selective 
CDK4/6 inhibitors, including ribociclib, abemaciclib and palbociclib, has allowed targeting of 
tumour types where CDK4/6 plays a pivotal role in the G1-S cell cycle transition with an 
improved therapeutic window between cancerous and normal cells. Pivotal phase III trials 
with palbociclib in advanced oestrogen receptor (ER) positive breast cancer have 
demonstrated substantial improvement in progression free survival with a well-tolerated 
toxicity profile. Mechanisms of acquired resistance to CDK4/6 inhibitors are beginning to 
emerge that may identify rational post-CDK4/6 therapeutic strategies. Selective CDK4/6 
inhibitors face challenges in extending beyond ER positive breast cancer, and it will likely be 
necessary to identify both biomarkers predictive of response and combination therapies to 
optimise CDK4/6 targeting.  
 
Introduction 
Aberrant proliferation and deregulated cell division is one of the key hallmarks of cancer, and 
identifying therapeutic targets to block cell division has been a common approach to cancer 
treatment. For a cell to divide it must progress through a pre-determined number of stages 
regulated by a complex regulatory network termed the cell cycle, a process highly conserved 
between eukaryotes1.  Each stage of the cell cycle must be passed through in turn with strict 
control exercised by signalling checkpoints, for example precluding progression in the 
presence of genetic damage2.  Transition from one stage in the cell cycle to the next is 
controlled by the cyclin dependent kinases, activated by their partner cyclins. CDKs have 
therefore been long regarded as promising targets for cancer therapies, although many of 
the early first generation CDK inhibitors failed in clinical development 3, 4, at least in part as 
non-selective pan-CDK inhibition was toxic5. 
These issues appear to have been overcome by more selective targeting of CDK4 and 6, a 
pair of kinases similar in structure and function that mediate transition from G0/1 to S phase. 
Three of these new CDK4/6 inhibitors – abemaciclib, palbociclib and ribociclib - have 
emerged through early phase trials as agents with promising anti-cancer activity and 
manageable toxicity, each with phase III trials in progress.  Palbociclib is the agent furthest 
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through development, having received accelerated approval from the US FDA in February 
2015 and also reporting recent pivotal phase III data; both of these in the setting of hormone 
receptor-positive advanced breast cancer, a disease in which the cyclin D/CDK4 axis is 
known to be critical6, 7. Further work is required to facilitate optimal selection of patients and 
to tackle the inevitable emergence of resistance in the metastatic setting.  In this review we 
discuss the biological rationale for targeting CDK4/6, review the available clinical evidence to 
date for the agents most advanced in development, and discuss the challenges facing 
scientists and clinicians with regards optimising their use.   
 
Targeting the cell cycle through CDK4/6 in cancer 
CDK4/6 and the classical view of G1/S phase transition 
The cell cycle is orchestrated by the interaction of cyclins with their partner serine/threonine 
cyclin-dependent kinases (CDKs). The importance of CDKs to the cell cycle was first 
elucidated in cdc28/cdc2 (the homologs to CDK1 in humans) in budding and fission yeast 
respectively8, 9, with the interacting cyclins described a decade later10, 11.  It would take a 
further ten years for the homologs to be confirmed in mammalian systems and for the cyclin-
CDK nomenclature to be adopted12, 13.  To enter the cell cycle a cell must progress from G1 
to S phase via the restriction point, a transition in part governed by the retinoblastoma 
protein (RB) and usually regulated through perturbations in a delicate balance between pro- 
and anti-mitotic signals.  Although mitogenic signalling is critical for entry into the normal cell 
cycle, its importance is greatly reduced once the cell has entered S phase14.  
The classical view of the initiation of the cell cycle has the D-type cyclins, cyclins D1, D2 and 
D3, as the key drivers 15-18 (Figure 1A, 1B).  The expression level of the D type cyclins is 
controlled by growth factor signalling, with transcription, turnover and nuclear transport all 
dependent on mitogenic signalling19-21.  In early G1, a pro-mitotic signalling balance results 
in increased expression of the D-type cyclins, which complex with and activate CDK4/6.  
This complex subsequently phosphorylates RB, and the other RB-like,‘pocket proteins’ p130 
and p107, at a number of positions 22-24.  In its hypophosphorylated state, RB represses 
transcription of genes necessary for cell cycle progression through binding to the 
transactivation domain of the E2F transcription factor family of proteins25-28.  Increasing 
phosphorylation of RB by the cyclin D/CDK4 complex reduces inhibitory control of RB on the 
E2F transcription factor family. This initiates a positive feedback loop, as the E2Fs promote 
transcription of the E type cyclins, activating CDK2 and other proteins important for initiation 
of S phase and DNA synthesis29, 30 (Figure 1B).  CDK2-cyclin E further phosphorylates RB, 
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reducing E2F inhibition and promoting S phase entry.  During S phase, CDK2 complexes 
with cyclin A and mediates transcriptional control of DNA synthesis31-33.  Throughout the 
progression through S phase and G2, RB remains hyperphosphorylated, returning to its 
hypophosphorylated state only following mitosis34-36.   
Although regulation of the E2F family of transcription factors remains the best described 
mechanism through which RB exerts control over the cell cycle, there are likely to be others 
as RB interacts with over 100 other proteins, most of which are poorly described37.  
Furthermore, there is evidence that RB exerts transcriptional control through chromatin 
remodelling; phosphorylation of RB leads to a weakening of its interaction with histone 
deacetylase and modulation of cyclin E and cyclin A transcription through its forming of 
regulatory complexes with SWI/SNF 38, 39.    
The INK4 and CIP/KIP proteins also regulate and control cyclin D-CDK4/6 activity, known 
collectively as the cyclin dependent kinase inhibitors (CKI) 19.  The INK4 group consists of 4 
structurally-related proteins, p16INK4A, p15INK4B, p18INK4C and p19INK4D, which specifically bind 
to CDK4 and CDK6 and have limited affinity for other CDKs 40-43.   Of the INK4 group, p16 is 
the best described and is induced by a number of cellular mechanisms such oncogenic 
signalling, senescence, TGFβ and contact inhibition44-46 (Figure 1A). Increased expression of 
p16 is a hallmark of tumours where functional RB protein has been lost. The CIP/KIP family 
is comprised of 3 proteins, the ubiquitously expressed p27 and p21, and a third member, 
p57, which is expressed in a limited number of tissues47-52.  In contrast to the INK4 family, 
the CIP/KIP proteins are able to bind to all the CDKs involved in the cell cycle to varying 
degrees and have both a positive and negative regulatory role.  The control exerted through 
these two groups of proteins on the G1-S transition is complex and interlinked, incorporating 
a number of feedback loops.   The best known inhibitor of cyclin D/CDK4 is p16, which 
contributes to G1 arrest in two ways.  Firstly, to become functional, CDK4 requires 
cytoplasmic, post-translational folding in a complex involving HSP90, an interaction 
disrupted by p1653-55.   In addition, p16 can bind to CDK4 directly and inhibit its catalytic 
activity40, 55.  The combination of these two mechanisms results in G1 arrest in cells with 
functional RB, but not RB-deficient cells56.  In contrast, the CIP/KIP proteins p21 and p27 
can stabilise the formation of cyclin D/CDK4 complexes, sequestering these proteins 
facilitating activation of CDK257-61 (Figures 1A, 1B).   
Non-classical G1/S phase transition and CDK4/6 inhibitor efficacy 
The classical view of G1/S phase transition has cyclin D and CDK4/6 as the key initiators of 
G1/S transition with CDK2 activity dependent on prior activation of CDK4/6 (Figure 1A, 1B).  
However, doubts over this classical view of G1-S phase transition were raised by cdk4 and 
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cdk6 knockout mice. Cdk4-deficient mouse models were viable but small in size with 
reproductive and endocrine dysfunction62-64. Similarly Cdk6-deficient models were also 
viable, but with hypocellularity in the thymus and spleen, and with a small reduction in 
peripheral blood cells,65.  The lack of a severe phenotype in these single knockout mice was 
assumed to be due to compensation between cdk4 and cdk6. Surprisingly, although double 
knockouts for cdk4 and cdk6 succumbed to anaemia in the late stages of embryonic 
development, many non-haematological cell types showed normal proliferation65.  In 
addition, embryonic fibroblasts without cdk4 and cdk6 still entered S phase, although at a 
reduced efficiency, with evidence that D-type cyclins interacted with cdk265.  Although 
murine models may be limited in predicting CDK dependency in human cells, the phenotype 
of the cdk4/6 knockout mouse predicted with high accuracy the toxicity profile seen with 
selective CDK4/6 inhibitors. The architecture of the classical view of the cell cycle, with the 
restriction point at G1/S, has also been challenged by the demonstration that CDK2 activity 
may persist directly after mitosis, with pre-mitosis levels of CDK2 and p21 activity predicting 
the fate of whether post-mitosis daughter cells continue to cycle or become quiescent 66.   
Despite caveats in interpreting murine and in vitro models, it seems the classical view of cell 
cycle entry, with the necessary role for CDK4/6, is likely overly simple in many cell types. As 
well as CDK4/6, other CDKs can initate cell cycle entry due to redundancy between CDKs 67, 
68, and as such CDK4/6 is potentially redundant in these cells (Figure 1C). The exact 
mechanisms that underlie redundancy have been incompletely described, although binding 
of cyclin D1 to CDK2 65, 69 and dysregulation of cyclin E expression may contribute (Figure 
1C). CDK3 can also contribute to cell cycle entry, phosphorylating RB at the G0/G1 
transition70.  
Leveraging cell cycle biology to find a therapeutic window 
The ideal CDK-targeted therapy would block the CDK-mediated signalling in malignant cells 
but spare the aspects of CDK activity critical to normal cell function to avoid toxicity.. Murine 
embryos lacking cdk1 fail to develop beyond the blastocyst stage68, suggesting that inhibition 
of CDK1 by non-specific inhibitors could affect most or all cell types and result in toxicity.  In 
addition, non-specific targeting of CDKs would inhibit CDKs 7, 8 and 9 whose functions are 
less well-described but include regulation of basal transcription, with CDK 7 also contributing 
to the cell cycle through its role as a CDK-activating kinase (CAK)71-76.  This challenge in 
finding a therapeutic window with CDK inhibitors was reflected in the early clinical 
experience of pan-CDK inhibitors such as flavopiridol and roscovitine.  Flavopiridol is a semi-
synthetic flavone with activity against CDKs 1, 2, 4, 6, 7 and 9 and was extensively 
investigated in early phase trials. Responses were seen in phase II studies in 
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haematological malignancies, notably chronic lymphoid leukaemia, but dosing was limited by 
toxicity77-82.   Roscovitine, a purine-based compound active against CDKs 1, 2, 5, 7 and 9, 
failed to demonstrate convincing clinical activity in two phase I studies83, 84.  The toxicity 
profile of roscovitine included nausea, vomiting and fatigue in addition to hepatic dysfunction 
and electrolyte abnormalities.  Flavopiridol caused fatigue, but also diarrhoea and a degree 
of myelosuppression78, 79. It is difficult to delineate to what degree these toxicities were the 
result of on-target effects. Roscovitine, with less activity at CDK4/6 (IC50 > 10µm), caused 
less myelosuppression, seen with both flavopiridol and the selective CDK4/6 inhibitors, both 
of which inhibit CDK4 at nanomolar concentrations (flavopiridol CDK 4 IC50 100nm, 
palbociclib CDK 4 IC50 11nm)
5. 
More selective targeting of CDK4/6 has a number of potential advantages over less selective 
inhibitors. Many normal cell types in the body may be capable of initiating the cell cycle 
despite CDK4/6 inhibition65. Additionally, in contrast to the cytotoxic effects of less selective 
CDK inhibitors, CDK4/6 inhibitors are usually observed to be cytostatic, which may further 
limit their potential for clinical toxicity, although CDK4/6 inhibition-induced cell death has 
been noted in T cell leukaemia cell lines and xenografts85, 86.  
 
Selecting target groups - the CDK4/6 axis deranged in cancer 
Selection of target groups for CDK4/6 inhibitors relies on identification of tumour types where 
CDK4/6 drives G1/S transition, and where the effects of CDK4/6 inhibition cannot be 
rescued by alternative CDKs. Aberrations in the cyclin D-CDK4/6 axis are frequent in cancer. 
Cyclin D activity is increased in a number of malignancies, a notable example being mantle 
cell lymphoma.  This is characterised by the t(11;14)(q13;q32) translocation that juxtaposes 
CCND1 with the IGH immunoglobulin heavy chain locus, resulting in the over expression of 
cyclin D187-90.  Amplification and over expression of cyclin D has been described in head and 
neck cancers91-94, breast cancers95-99, non-small cell lung cancers100, 101, oesophageal 
cancers102, 103,  melanoma 104-106, and glioblastoma107, 108.   
A further potential activating mechanism in the cyclin D1/CDK4/6 axis is over-expression of 
the kinases, although activating somatic mutations are very rare.  Amplifications of CDK4 are 
seen in well-differentiated and de-differentiated liposarcomas, as part of a 12q14.15 
amplicon, though this also features MDM2 and HMGA2 and there is uncertainty over which 
genes are the key drivers109-111.   Somatic amplifications in CDK4 have been noted in 
melanoma and glioblastoma 105, 112, 113 and CDK6 in squamous cell oesophageal 
carcinoma114 and a small number of B-cell lymphoproliferative disorders which have 
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undergone translocations involving 7q21115-117.  The relationship between amplification of 
CDK4, CDK4 activity, and CDK4/6 inhibition is unclear, with reports that both increased 
expression and amplification is associated with resistance to selective CDK4/6 inhibition112, 
118. Germline CDK4 mutations in the p16-binding domain have been reported in a small 
number of families with predisposition to melanoma119-121.   
Loss of p16 function is common in cancer and implies absence of the primary inhibitory 
brake on CDK4/6-driven signalling.  Homozygous deletions of p16 are seen in pancreas, 
bladder, breast and prostate cancers and glioblastoma122-124.  An important role for p16 is 
also implied in melanoma by the common deletion of CDKN2A in melanoma-prone 
kindreds125. Conversely, loss of RB results in constitutive activation of E2F, cyclin E1 and 
CDK2 expression, and therefore loss of reliance on CDK4/6 to initiate G1-S phase 
transition126, 127. 
Breast cancer subtype dependency on cyclin D1 
In luminal oestrogen receptor (ER) positive breast cancer, representing approximately 75% 
of breast cancer, ER signalling activates the cyclin D promoter, and in many ER positive 
breast cancers cyclin D1 is expressed at a high level with or without CCND1 gene  
amplification 95, 97. Cyclin D1 is also known to have a number of CDK-independent functions 
that likely contribute to breast cancer pathogenesis 128. Cyclin D1 binds to and facilitates ER 
transcription activity 128, likely reinforcing the dependence of ER positive luminal breast 
cancer on cyclin D1. In contrast, expression of cyclin E1 is low in ER-positive breast cancer 
129, and  RB1 is rarely inactivated by mutation130.  
Therefore ER-positive, luminal breast cancer presents the archetypal model for CDK4/6 
inhibitors, reflecting the particular dependence of luminal breast cancer on cyclin D1 to 
initiate G1-S phase transition.  In addition, as breast cancers become resistant to endocrine 
therapy they remain dependent on cyclin D1 and CDK4 to drive proliferation131. In contrast to 
luminal breast cancer, basal-like triple negative breast cancer is characterised by loss of RB 
132-134 and by high expression of cyclin E1129.  Consequently basal-like breast cancer cell 
lines are resistant to CDK4/6 inhibition126. High expression of cyclin E2 has been found in 
luminal B breast cancers and is correlated with shorter time to distant progression135, 
although the role of Cyclin E2 in CDK4 inhibitor sensitivity remains to be determined 135.   
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Preclinical development of the selective CDK4/6 inhibitors 
Three CDK4/6 inhibitors have currently reached early phase trials, abemaciclib (LY-
2835219, Eli Lilly), palbociclib (PD-0332991, Pfizer), and ribociclib (LEE011, Novartis), with 
phase III data now available for palbociclib.  These orally-administered compounds of similar 
structure (figure 2) bind in the ATP-binding pocket of CDK4 and CDK65, 136 (figure 3A), and 
all show a high degree of selectivity over CDK1 and CDK2. Preclinical work in cell lines and 
xenografts has focused on malignancies with established derangements in the cyclin 
D/CDK4/p16 axis and has revealed the predominant effect of CDK4/6 inhibitors to be 
cytostatic rather than inducing cell death and apoptosis.  
Abemaciclib inhibits CDK4/6 at low nanomolar concentrations and has been shown to to 
reduce the phosphorylation of RB in colorectal and melanoma xenografts, inducing G1 
arrest137, 138.  In addition to CDK4 and 6, abemaciclib also reported activity at CDK9 although 
it is unclear whether this translates into inhibition of CDK9 in cellular activity138.    
Abemaciclib was also able to effect growth regression in vemurafenib-resistant melanoma 
models, where cyclin D1 was noted to be elevated in conjunction with MAPK pathway 
reactivation139.   
Palbociclib is also active at low nanomolar concentration at CDK4 and 6, but with limited 
activity against other CDKs or tyrosine kinases140, 141.  Palbociclib was active in mantle cell 
lymphoma xenografts 142, and in glioblastoma cell lines, where in addition to functional RB 
co-deletion of CDKN2A was found to predict sensitivity112, 143, 144.  In ovarian cell lines 
response was found to be most marked in cancers with low p16 expression, with deletions in 
CDKN2A associated with response and amplification of CCNE1 associated with 
resistance127. Work in renal cell carcinoma identified low E2F1 expression as another 
potential marker for sensitivity in addition to p16 loss145.   Additionally, palbociclib has 
demonstrated activity in acute myeloid leukaemia and myeloma, combined with bortezomib, 
in both cell line and xenograft models, although particular biomarkers for sensitivity were 
less clear in these experiments146-148.  It has also shown activity in RB-replete prostate 
cancer149 and in hepatocellular carcinoma, where curiously some activity in RB-deficient 
cells was observed, potentially through compensation via other pocket proteins150. 
In breast cancer models, palbociclib shows synergy with trastuzumab and tamoxifen 
treatment in HER2-amplified and ER-positive cells respectively, which are both luminal 
cancer types and therefore reliant on cyclin D1 to activate CDK4/6 99, 126, 151, 152.  Synergy with 
endocrine therapy in ER-positive breast cancer at least in part reflects the simultaneous 
effects of endocrine therapy suppressing cyclin D1, and palbocicilb inhibiting CDK4/6. In the 
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presence of CDK4/6 inhibition alone, persistent cyclin E2 continues to allow a low level of S 
phase entry153, and synergy is seen with endocrine therapy through suppressing residual 
cyclins. Treatment with palbociclib also results in growth arrest in breast cancer cell lines 
with in vitro derived resistance to endocrine therapy, but which remain dependent on 
CDK4/6154.  
Ribociclib inhibits CDK4/6 at nanomolar concentrations155 and as a single agent ribociclib 
has demonstrated growth inhibition in neuroblastoma and liposarcoma cell lines, resulting in 
G1 arrest, a reduction in the phosphorylation of RB at Ser780 and Ser807/811  and 
significantly reduced tumour burden seen in xenografts156, 157. 
Efficacy and toxicity in early phase trials 
Early phase studies into the selective CDK4/6 inhibitors showed a manageable toxicity 
profile with indications of promising clinical activity.  Single agent efficacy appeared to 
manifest as predominantly as stable disease, hypothesised to be as a result of the cytostatic 
nature of these agents, although responses were demonstrated in particular in combination 
with endocrine therapy in breast cancer. Toxicity profiles vary between the inhibitors for 
reasons that are not understood, but which may have ramifications for optimising their 
clinical use and in combination with other therapies. 
Abemaciclib 
The initial phase I study for abemaciclib recruited a cohort of 55 patients of multiple tumour 
types, 52% experienced diarrhoea, 5% at grade 3158.  Neutropaenia was far less prevalent 
than in the trials of ribociclib and palbociclib, allowing for continuous dosing.  One patient 
with a homozygous deletion of CDKN2A had a partial response. In a further phase I trial in 
non-small cell lung cancer, 51% achieved at least stable disease with 41% of patients on 
treatment for at least 4 cycles159.  In the metastatic breast cancer cohort of the phase I study, 
33% had a partial response, despite relatively heavy pre-treatment, with a progression free 
survival for 9.1 months in 36 ER-positive patients160.  
Palbociclib 
Two of the phase I studies of single agent palbociclib were conducted in RB-expressing 
cancers, with efficacy manifesting predominantly as stable disease161, 162. The third study 
involving 17 patients with mantle cell lymphoma resulted in 5 of the 17 patients experiencing 
a progression-free survival of over 12 months163. Similar dose-limiting toxicities were seen 
across the studies with grade 3 or 4 neutropaenia the most common.  This required 
intermittent therapy for recovery of neutropaenia, establishing the dose of 125mg daily with 3 
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weeks on treatment and the fourth week off 161, 162.  Three of the phase I patients enrolled 
with teratoma syndrome, refractory to surgery and with confirmed strong expression of RB, 
achieved at least stable disease and remained on treatment for between 18 and 24 
months164.  A further similar case in a paediatric patient has also been reported165.   A phase 
II study looking at this further treated 30 patients with relapsed, RB-proficient germ cell 
tumours and observed 8 patients with a progression free survival greater than 24 weeks166.   
Thirty seven patients with RB-proficient breast cancer were included in a phase II study of 
palbociclib as a single agent, with two partial responses and a further 5 patients achieving 
stable disease for at least 6 months despite heavy pre-treatment167. A phase II trial recruiting 
exclusively patients with liposarcoma found that 66% of 29 evaluable patients had not 
progressed at 12 weeks, with one patient having a partial response168. 
Ribociclib 
Ribociclib has been tested as a single agent in phase I with two dosing schedules, either 
continuously or 3 weeks on, 1 week off.  In a cohort of 132 advanced solid tumours and 
lymphomas the predominant dose-limiting toxicity was cytopaenias, particularly neutropaenia 
and leukopaenia, with the most common side effects of all grades otherwise being nausea 
and fatigue 169.  Two patients experienced a partial response, one with melanoma and one 
with breast cancer, both of them with amplification of CCND1.  In a trial of 14 patients with 
NRAS-mutated melanoma who received ribociclib in conjunction with binimetinib, a MEK 
inhibitor, 6 had a partial response170.  There are ongoing phase Ib/II studies examining 
ribociclib in combination with BYL719, a PIK3CA inhibitor, or everolimus in conjunction with 
an aromatase inhibitor in post-menopausal breast cancer.  Although limited data have been 
reported, no safety concerns have been raised171, 172.  
Differences between CDK4/6 inhibitors 
Whilst the early stage efficacy and toxicity of palbociclib and ribociclib are very comparable, 
abemaciclib shows differences.  Abemaciclib has a different toxicity profile with less bone 
marrow suppression and increased diarrhoea. In terms of efficacy it possibly has a higher 
response rate as a single agent in pre-treated breast cancer. Of the three inhibitors, 
abemaciclib is the more potent against CDK4 as opposed to CDK6 on in vitro kinase assays. 
However, it is unclear whether this could explain possible increased activity or the more 
marked diarrhoea, and the potential role of CDK9 inhibition by abemaciclib is unknown.  
There appear to be differences in absorption across the blood-brain barrier between the 
inhibitors although the evidence is partially conflicting.  Abemaciclib appears better absorbed 
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across the blood brain barrier than palbociclib173, 174, an observation potentially relevant for 
the treatment of patients with brain metastases or CNS tumours.  Nonetheless, there are 
case studies involving effective treatment of patients with palbociclib for intracranial 
teratoma165. 
 
Randomised studies of CDK4/6 inhibitors in breast cancer 
Although later stage randomised studies are recruiting with CDK4/6 inhibitors in multiple 
cancer types, the only published evidence to date comprises data from breast cancer, where 
our discussion will focus. 
Two randomised studies have reported with palbociclib in hormone receptor positive 
advanced breast cancer. The first study to report was the randomised open-label phase II 
study, PALOMA-1/TRIO-18, conducted in patients with advanced ER-positive, HER2-
negative breast cancer untreated for advanced disease. Patients had either no prior  
adjuvant aromatase inhibitor (AI) or had stopped adjuvant AI therapy at least a year prior to 
relapse6. One hundred and sixty five patients were randomised between letrozole alone or in 
combination with palbociclib, with the study recruiting two consecutively accrued cohorts.  
The first cohort recruited all ER-positive HER2-negative, the second cohort further restricted 
based on either amplification of CCND1 or loss of p16.  The intention was for the first cohort 
to be exploratory, and second the primary cohort for PFS analysis.  However, after an 
unplanned interim analysis demonstrated significantly improved PFS and a low probability of 
a difference with selection, the study was amended to stop accrual to the CCND1 and p16 
selection and to analyse both cohorts together.  At the final PFS analysis and a median 
follow up of 30 months, this analysis demonstrated an improvement in median PFS from 
10.2 months to 20.2 months with the addition of palbociclib to letrozole (HR 0.488, 95%CI 
0.319 – 0.748, p = 0.0004, figure 4).  Consistent with prior studies the principal toxicity was 
neutropaenia, although no cases of febrile neutropaenia were reported.  Low grade (1-2) 
fatigue and nausea were also more prevalent with the addition of palbociclib (36% v 22% 
and 23% versus 12% respectively), along with slightly higher levels of the side-effects 
typically seen with aromatase inhibitors such as hot flushes and arthralgia. 
The PALOMA 1/ TRIO 18 study served as the basis for accelerated approval of palbociclib 
by the FDA on February 3, 2015.  
Phase III registration studies 
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The first phase III study to report with a CDK4/6 inhibitor was the PALOMA-3 study, a double 
blind, randomised controlled trial of 521 patients with advanced, hormone receptor positive, 
HER2-negative breast cancer that had progressed on prior endocrine therapy. Patients were 
randomised in a 2:1 ratio between palbociclib and fulvestrant versus placebo and 
fulvestrant7, fulvestrant being a selective oestrogen receptor degrader with activity in breast 
cancer after progression on prior endocrine therapies175. The study was positive at the pre-
planned interim analysis, with revealed a median PFS 9.2 months for the 
palbociclib/fulvestrant arm compared with 3.8 months with placebo/fulvestrant, (hazard ratio 
of 0.42, 95%CI 0.32 – 0.56, p < 0.001, figure 4).  The majority of enrolled women were post-
menopausal, although 21% were pre-menopausal and treated with a GnRH agonist to 
induce ovarian suppression.  
Consistent with PALOMA-1/TRIO18 the toxicity profile included frequent haematological 
adverse events, but also a small increase in mostly grade 1/2 fatigue, alopecia and 
stomatitis.  Although a relatively large proportion of the palbociclib arm experienced grade 3 
or 4 neutropaenia (62%) and 31% required a dose reduction, the palbocicilb dose intensity 
was 91.7% and only 2.6% patients stopped palbociclib due to adverse effects.  As in 
PALOMA-1/TRIO18, despite the high rate of neutropaenia the rate of febrile neutropaenia 
was minimal at 0.6% in both arms.  Infections, mainly of grade 1 or 2 severity, were seen 
more frequently with palbociclib (32.4% versus 24.4%).  Global quality of life was 
significantly improved on palbociclib compared to placebo, as measured using the QLQ-C30. 
The PALOMA3 study will lead to registration of palbocicilb in many territories. 
In terms of ongoing phase III trials the confirmatory PALOMA-2/TRIO-22 study, testing the 
combination of palbociclib/letrozole versus placebo/letrozole in first-line treatment of 
advanced ER positive breast cancer, has completed accrual but is yet to report.  Both 
abemaciclib and ribociclib are also currently in phase III trials.  MONARCH-2 
(NCT02107703), with a similar design to PALOMA-3 but testing abemaciclib is currently 
recruiting, and the MONALEESA-7 trial (NCT02278120) is examining the combination of 
ribociclib with endocrine therapy in pre-menopausal women with advanced hormone 
receptor positive breast cancer176, 177. 
 
Patient selection, anticipating resistance and future challenges 
Though there are a number of plausible biomarkers for CDK4/6 inhibition, for example cyclin 
D, CDKN2A and RB (figure 3B), the only selection marker currently confirmed in the clinical 
setting is ER positivity in breast cancer.  It is anticipated that further positive selection 
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markers may be difficult to identify for ER positive breast cancer, as this subtype of breast 
cancer is often dependent on cyclin D1 and therefore CDK4/6 to drive proliferation. Of note, 
amplification of CCND1 and/or loss of CDKN2A  status offered no further selection 
advantage in the phase II PALOMA-1 study 6, although this data is very limited and requires 
further confirmation.  
Further work remains to identify the potential biomarkers of resistance to CDK4/6 inhibitors 
in ER positive breast cancer. RB loss is an obvious candidate, but loss of RB is rare in ER 
positive breast cancer130, although there are few data on whether RB loss changes in 
frequency with resistance to prior therapy. Amplification of E2F or loss of p21, commonly 
observed in cancers and linked to tamoxifen resistance178, are two plausible markers of 
resistance that have been proposed (figure 3B). Identification of the potential of cyclin E-
CDK2 to rescue CDK4/6 inhibition, potentially through assessment of cyclin E levels, or 
through gene expression predictors of RB1/E2F proficiency could be interesting future 
approaches. In terms of resistance, breast cancer cell lines with derived resistance to 
palbociclib select loss of RB and amplification of cyclin E1153, favouring the non-classical G1-
S transition phenotype. Cell lines with acquired cyclin E1 amplification show sensitivity to 
CDK4/6 and CDK2 combination inhibition, potentially identifying a therapeutic strategy for 
cell lines with acquired resistance153. 
Other tumour types likely show subtype sensitivity to CDK4/6 inhibitors such as mantle cell 
lymphoma. However, in many other tumour types biomarkers are likely to be important in 
identifying selective dependence on cyclin D1-CDK4/6. The phase II/III Lung-MAP trial has 
an experimental arm where patients with recurrent squamous cell carcinoma are allocated to 
palbociclib on the basis of aberrations in CDK4 and CCND1-3 (NCT02154490). The 
SIGNATURE trial includes patients treated with ribociclib on the basis of cyclin D/p16/CDK4 
aberrations. More information regarding the efficacy of various biomarkers will become 
available with ongoing biopsy-driven studies examining CDK 4/6 inhibitors in the neo-
adjuvant setting and at progression on CDK 4/6 therapies.   
Combination therapy with CDK4/6 inhibitors 
Which endocrine therapy in ER positive breast cancer? 
CDK4/6 inhibitors have been developed almost exclusively in combination with endocrine 
therapies in ER positive breast cancer, based on sound preclinical evidence of combination 
efficacy. The selection of the most active endocrine therapy for an individual patient is likely 
important for combination, though also dictated by the licensed indications. For endocrine-
naïve patients, combination with an aromatase inhibitor is likely advantageous, as per 
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PALOMA1, whereas in patients with endocrine pre-treated breast cancer fulvestrant is 
suitable, as per PALOMA3. There are no data at this time for continuing the endocrine 
therapy beyond resistance whilst adding in CDK4/6 inhibitor, and therefore it is uncertain if 
this approach would be efficacious. 
In breast cancer particularly there appears to be a strong case for combining PI3K inhibitors 
and mTOR inhibition with CDK4/6 inhibitors (figure 5).  If, as has been shown in breast 
cancer cell lines, endocrine resistance is in part mediated through ligand-independent ER 
interacting with CDK4 and with PI3K hyper-activation131, and CDK4/6 inhibition can 
overcome resistance to both PI3K inhibition179 and endocrine therapy126, then combination 
could prevent the emergence of resistance (table 1).  Similarly, CDK4/6 inhibition could also 
offer a means to address the activity of ligand-independence conferred by activating 
mutations in ESR1180-182. There is also a strong rationale for the use of CDK4/6 in 
combination with HER2-directed therapy in HER2-amplified breast cancers.  Increased 
cyclin D1 is found in cellular and mouse models of HER2 over expression and in transgenic 
mice with activating mutations in HER2151, with evidence that cyclin D1 and CDK4 is 
required for tumorigenesis in these cancers183.  Consistent with this, palbociclib was 
observed to be synergistic with trastuzumab in HER2-amplified cells126.  This combination is 
being taken forward in a number of early phase trials (NCT01976169, NCT02448420). 
Combination strategies in other malignancies 
A number of combination strategies with CDK4/6 inhibitors are also being pursued in 
haematological malignancies, including with bortezomib in myeloma184, with preclinical 
evidence to support the combination of CDK4 inhibition with ibrutinib or PI3K inhibition in 
mantle cell lymphoma 185, 186 (table 1). There is also evidence for CDK4/6 inhibition in 
combination with MAPK pathway inhibition with MEK or BRAF inhibitors in melanoma187 and 
colorectal cancer188 (figure 5). CDK4/6 inhibition can also re-sensitise melanoma cell lines 
with BRAF V600E mutation to vemurafenib once resistance has developed139. The 
mechanism of all these combinations in part reflects suppression of cyclin D/E levels to limit 
the ability of alternative CDKs to bypass CDK4/6 inhibition. RAS signalling has also been 
shown to promote cycling by reducing levels of p27189. 
 In lung cancer cell lines and xenografts, knock down of CDK4 was seen to produce a 
greater degree of inhibition in KRAS-mutant cells than those with KRAS wild type190, in 
keeping with previous work which had suggested a degree of synthetic lethality between 
Cdk4 ablation and KRAS activity191.  In addition, the potential of using CDK4/6 inhibitors to 
prevent repopulation between cycles of chemotherapy has been raised for cancers 
dependent on CDK4/6, but this presents substantial scheduling challenges in the clinic. A 
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large number of early stage clinical trials examining combinations of therapies with CDK4/6 
inhibitors are currently under way.   
Conclusions 
Targeting the cell cycle machinery directly in cancer treatment is a logical therapeutic 
approach, but one that has proved challenging without appropriate selection. Selective 
CDK4/6 inhibitors combined with appropriate selection of the target population now has 
proven efficacy, and will change the standard of care for patients with advanced ER positive 
breast cancer.  Extending the benefit outside ER positive breast cancer will require 
identification of cancer subtypes that show dependence on the cyclin D/CDK4/6/RB 
pathway, the identification of effective clinical biomarkers to expand indications, and effective 
drug combinations to mitigate resistance. 
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Figure legends 
Figure 1. Classical and non-classical models of the cell cycle in RB-proficient cells. 
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A. Resting cells in G0/early G1. The retinoblastoma protein RB is hypophosphorylated and 
inhibits the transcriptional activity of the E2F family of proteins.  The INK4 protein p16, acts 
as a brake on the activation of CDK4/6.  
B. The classical model of G1/S transition. Mitogenic and oestrogen receptor signalling 
upregulates the transcription of the D type cyclins. The D-type cyclins complex with CDK4/6 
to phosphorylate RB, activating the E2F family of proteins that results in transcription of 
cyclins E, A and CDK2.  The phosphorylation of RB also effects chromatin remodelling in 
favour of transcription (not shown). CDK4/6/cyclin D complexes sequester the CIP/KIP 
proteins, reducing their inhibitory effect on CDK2, and reducing the threshold for activation of 
CDK2 by E-type cyclins.  As cyclin E rises, it complexes with CDK2 to hyperphosphorylate 
RB, forming a positive feedback loop via E2F to push the cell from G1 to S phase.  
C. The non-classical model of G1/S transition. CDK2 is active in early G1 complexing with 
cyclins E and potentially cyclin D directly. Both CDK4/6 and CDK2 phosphorylate RB, and 
drive G1/S transition. The mechanisms through which CDK2 becomes active in G1 without 
requiring prior CDK4/6 activation are poorly understood, although in some rapidly 
proliferative cells CDK2 remains active immediately after mitosis. 
D – D-type cyclins, E – E-type cyclins,  A – cyclin A, CDK2 – cyclin dependent kinase 2, 
CDK4/6 – cyclin dependent kinase 4 or 6,  RB – retinoblastoma protein, P = phosphate 
group 
 
Figure 2.  The structure of selective CDK4/6 inhibitors with the half-maximal inhibitory 
concentrations (IC50) for a number of cyclin-dependent kinases. 
 
Figure 3. The cell cycle and the role of CDK4/6 inhibition. 
A. G1 arrest caused by CDK4/6 inhibition.  CDK4/6 inhibitors interact with CDK4 and 6 to 
prevent their kinase activity via ATP-competitive binding.  The cyclin D/CDK4/RB/p16 axis is 
commonly deranged in cancer, for example through over expression of cyclin D or under 
expression of p16.  In these cases CDK4/6 inhibitors can block the disinhibited 
phosphorylation of RB, leading to G1 arrest in the absence of an escape mechanism. 
B. Potential mechanisms of resistance to CDK4/6 inhibition.  In cancer cells deficient in 
RB, the E2F transcription family in constitutively active and CDK4/6 is redundant. In RB-
replete cells, overexpression of cyclin E or loss of the CIP/KIP proteins may bypass CDK4/6 
 26 
inhibition by activating CDK2. . E2F amplification is another posited mechanism for 
bypassing RB,  
D – D-type cyclins, E – E-type cyclins,  A – cyclin A, CDK2 – cyclin dependent kinase 2, 
CDK4/6 – cyclin dependent kinase 4 or 6,  RB – retinoblastoma protein, P = phosphate 
group, ciclib = CDK4/6 inhibitor 
 
Figure 4.  Activity of palbocicilb in advanced ER positive breast cancer 
A. Kaplan-Meier plot showing progression free survival for women with advanced, hormone 
receptor positive, HER2 negative breast cancer treated with either palbociclib and letrozole 
or letrozole alone in the PALOMA-1/TRIO-18 phase II study, taken from Finn et al 2015 
Lancet Oncology.  
B. Kaplan-Meier plot showing progression free survival for women with advanced, hormone 
receptor positive, HER2 negative breast cancer treated with either palbociclib and fulvestrant 
or fulvestrant and placebo in the PALOMA-3 study, taken from Turner et al 2015 NEJM. 
 
Figure 5. Combination therapy approached with  CDK4/6 inhibitors. 
A. The CDKs and cyclins act both in parallel and downstream of cellular signal transduction 
pathways and oestrogen signalling to promote cell cycle progression. Activation of the MAPK 
and PI3K pathways by receptor tyrosine kinases promotes cell cycle progression through 
upregulation of D and E type cyclins. RTK signalling therefore both activates CDK4/6 but 
may also promote CDK4/6 inhibitor bypass, potentially through promotion of cyclin E or 
through inhibition of p21/p27. Similarly oestrogen recepotor signalling in ER positive breast 
cancer may promote bypass of CDK4/6 inhibtion, with ER signalling in part facilitated by 
cyclin D1 binding. 
B. Promising strategies for combinatorial efficacy with CDK4/6 inhibition based on preclinical 
models include blockade of oestrogen receptor signalling with tamoxifen, aromatase 
inhibitors or SERDs, PI3K pathway blockade with PI3-kinase inhibitors and mTOR inhibition 
with rapalogs and MAPK pathway blockade with BRAF and MEK inhibitiors. 
RTK - receptor tyrosine kinase, PI3K – phosphoinositide-3 kinase, MAPK – mitogen-
activated protein kinase, mTOR – mammalian target of rapamycin, D – D-type cyclins, E – 
E-type cyclins,  A – cyclin A, CDK2 – cyclin dependent kinase 2, CDK4/6 – cyclin dependent 
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kinase 4 or 6,  RB – retinoblastoma protein, ER – oestrogen receptor, P = phosphate group, 
AI – aromatase inhibitor, SERD – selective oestrogen receptor degrader. 
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Table 1. Current clinical strategies using CDK4/6 inhibition, alone or in combination 
by cancer type and potential biomarker if available. 
Therapy Cancer Biomarker Evidence 
CDK4/6i plus 
aromatase inhibitor or 
SERD 
Hormone receptor 
positive advanced 
breast cancer 
ER positive Phase I, II and III
6, 7, 161, 
167
 
Preclinical
126
 
CDK4/6i plus 
endocrine therapy, plus 
PIK3CA/mTOR 
inhibiton 
Hormone receptor 
positive advanced 
breast cancer 
ER positive Phase I
172, 192
 
Preclinical
126, 131, 179
 
CDK4/6i plus HER2-
directed therapy 
HER2+ve breast 
cancer  
HER2-amplification Preclinical
99, 126
 
CDK4/6i plus 
bortezomib or 
dexamethasone 
Myeloma None Phase I/II
184
 
Preclinical
146, 147
 
CDK4/6i alone or in 
combination with 
ibrutinib and PI3K 
inhibition 
Mantle cell lymphoma t(11:14) deregulating 
CCND1  
Mutated Bruton 
tyrosine kinase 
Phase I
163
 
Preclinical
142, 185, 186
 
CDK4/6i alone Acute lymphoblastic 
leukaemia 
None Preclinical
85, 86
 
Combined CDK4/6i 
and FLT3 inhibition 
Acute myeloid 
leukaemia 
FLT3 Preclinical
148, 193
 
CDK4/6i alone Liposarcoma Not clear, CDK4 
amplification highly 
prevalent 
Phase II
168
 
Preclinical
157, 168
 
CDK4/6i alone Fusion positive 
rhabdomyosarcoma 
Absence of CDK4 
amplification 
Preclinical
118
 
CDK4/6i alone Teratoma RB replete Phase I and II
162, 164-166
 
CDK4/6i alone Glioma P16-deficient 
RB replete 
Preclinical
112, 143, 144, 194
 
CDK4/6i plus MEK 
inhibitor or BRAF 
inhibitor 
Melanoma NRAS mutation Phase I
158, 170
 
Preclinical
139, 187
 
CDK4/6i alone Oesophageal 
adenocarcinoma 
RB-replete Preclinical
195
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CDK4/6i alone Neuroblastoma Amplification of MYCN Preclinical
156
 
CDK4/6i alone NSCLC KRAS mutation Preclinical
190, 191
 
CDK4/6i alone or in 
combination with 
MAPK inhibition 
Colorectal cancer KRAS mutation Preclinical
140
 
CDK4/6i with TGF-β 
receptor inhibitors or 
IGF1R inhibitors 
Pancreatic cancer CDKN2A mutation Preclinical
196, 197
 
CDK4/6i alone  Ovarian cancer RB replete 
P16 deficient 
Preclinical
127
 
CDK4/6i alone Renal cell carcinoma Low expression/loss 
p15, p16 and E2F1  
Preclinical
145
 
CDK4/6i alone Hepatocellular 
carcinoma 
None Preclinical
150
 
CDK4/6i alone Prostate cancer RB replete Preclinical
149
 
 
